Australian Clinical Labs Ltd (AU:ACL) has released an update.
Australian Clinical Labs Limited has announced an update to their ongoing stock buy-back program, having purchased 125,000 ordinary fully paid shares on the previous day. The buy-back, which is taking place on the market, is part of the company’s strategy to re-invest in itself, a move that often signals confidence in future growth and can be of interest to investors.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.
